Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursNicolás Isambert, P. Fumoleau, Emmanuelle Bourbouloux et al.|European Journal of Cancer|2009Cited by 45